In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts gather to discuss “Heart Failure · Rebirth: Making the Broken Heart Beat Again”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-moderated by Prof. Xuanxuan Li, Shi Jia Zhuang Great Wall Hospital. Quest for Truth is honored to welcome two distinguished interview guests: Dr. Nazha Hamdani, Ruhr-Universität Bochum; and Prof. Chun Liang, Shanghai Changzheng Hospital.
In this segment, the discussion focuses on the therapeutic revolution in heart failure, from the traditional “golden triangle” to today’s “Fantastic Four” strategy. Prof. Gang Wu asks whether this shift reflects a deeper change in how clinicians understand heart failure: from an irreversible, progressive disease to a potentially reversible condition.
Dr. Nazha Hamdani explains that reversibility depends on the phenotype and cause of heart failure. She notes that heart failure with reduced ejection fraction has benefited from stronger therapeutic advances, with morbidity and mortality reduced over the past 15 years. However, for heart failure with preserved ejection fraction, progress remains limited, with recent specific options including SGLT2 inhibitors and GLP-1 receptor agonists in obese patients. She emphasizes that much work remains to reduce mortality and morbidity across all heart failure phenotypes.
Prof. Chun Liang discusses the situation in China, where heart failure with preserved ejection fraction accounts for a large proportion of cases. He notes that therapies such as ARNI and SGLT2 inhibitors may be important choices, while Chinese medicine is also being explored as part of heart failure management. Referring to research discussed at OCC 2026, he suggests that Chinese medicine may help improve microcirculation in the heart and could bring promising results in the future.